Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Menu

    Lenvatinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lenvatinib Mesilate: Drug Interactions and Important Consideratio
    Lenvatinib Mesilate: Drug Interactions and Important Consideratio

    29 May 2025

    // PRESS RELEASE

    https://www.qingmupharm.com/lenvatinib-mesilate-drug-interactions-and-important-considerations

    PRESS RELEASE
    29 May 2025
    Share Share
    Synthesis Methods of Lenvatinib Mesylate API
    Synthesis Methods of Lenvatinib Mesylate API

    07 Aug 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/synthesis-methods-of-lenvatinib-mesylate-api

    PRESS RELEASE
    07 Aug 2024
    Share Share
    Potential of Lenvatinib Mesylate in Liver Cancer Treatment
    Potential of Lenvatinib Mesylate in Liver Cancer Treatment

    15 Jan 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/potential-of-lenvatinib-mesylate-in-liver-cancer-treatment

    PRESS RELEASE
    15 Jan 2024
    Share Share
    Eisai's Kisplyx (lenvatinib mesilate) Receives Approval for Europe
    Eisai's Kisplyx (lenvatinib mesilate) Receives Approval for Europe

    26 Oct 2018

    // EMA

    https://www.ema.europa.eu/documents/product-information/kisplyx-epar-product-information_en.pdf

    EMA
    26 Oct 2018
    Share Share
    Eisai, MSD start marketing activity for LENVIMA
    Eisai, MSD start marketing activity for LENVIMA

    25 Oct 2018

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/25/11929/eisai-msd-start-marketing-activity-for-lenvima.html

    BIOSPECTRUM
    25 Oct 2018
    Share Share
    Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
    Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)

    07 Mar 2018

    // NASDAQ

    https://www.nasdaq.com/press-release/eisai-co-ltd-and-merck-enter-global-strategic-oncology-collaboration-for-lenvima-lenvatinib-mesylate-20180307-01372

    NASDAQ
    07 Mar 2018
    Share Share